Belgian guidelines for economic evaluations and budget impact analyses: third edition

KCE Reports 400C (2025)

In Belgium, cost-effectiveness is one of the criteria used by public authorities to assess applications for reimbursement of medicines and Class 1 medical devices, i.e. products for which the applicant claims added therapeutic value and for which a higher price may be charged. For other interventions as well (surgical procedures, vaccines, disease prevention strategies, screening programmes, etc.), economic evaluations and budget impact analyses provide valuable support for the efficient use of limited resources. This guideline is the result of the second update of the KCE guideline on economic evaluations in health and budget impact analyses. The aim is to improve the relevance, methodological quality, transparency and consistency of these economic evaluations of health interventions in Belgium.